Effects of menopausal hormonal therapy on occult breast tumors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 137, Issue , 2013, Pages 150-156

  Santen, Richard J ^a,c   Song, Yan ^a   Yue, Wei ^a   Wang, Ji Ping ^a   Heitjan, Daniel F ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Computer simulated tumor growth model; Estrogens; Occult breast cancer; Progestogen; Tissue selective estrogen complex (TSEC); Tumor doubling time

Indexed keywords

AROMATASE INHIBITOR; BAZEDOXIFENE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CANCER PREVENTION; CLINICAL TRIAL; FRACTURE; HORMONAL THERAPY; HUMAN; MAMMARY GLAND; MAMMOGRAPHY; MENOPAUSE; NONHUMAN; REVIEW; SALPINGOOOPHORECTOMY; XENOGRAFT;

COMPUTER SIMULATED TUMOR GROWTH MODEL; ESTROGENS; OCCULT BREAST CANCER; PROGESTOGEN; TISSUE SELECTIVE ESTROGEN COMPLEX (TSEC); TUMOR DOUBLING TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY;

EQUIDAE; MUS; MUS MUSCULUS;

EID: 84886599101     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.05.008     Document Type: Review

References (53)

1. H.G. Welch, and W.C. Black Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Annals of Internal Medicine 127 11 1997 1023 1028 (Pubitemid 27516615)
2. R.J. Santen, D.C. Allred, and S.P. Ardoin Postmenopausal hormone therapy: an Endocrine Society scientific statement [Review] [511 refs] Journal of Clinical Endocrinology & Metabolism 95 7:Suppl. 1 2010 (Suppl-Sus66)
3. S.A. Bartow, D.R. Pathak, W.C. Black, C.R. Key, and S.R. Teaf Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study Cancer 60 11 1987 2751 2760 (Pubitemid 17161808)
4. M. Nielsen, J.L. Thomsen, S. Primdahl, U. Dyreborg, and J.A. Andersen Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies British Journal of Cancer 56 6 1987 814 819 (Pubitemid 18048359)
5. P.S. Bhathal, R.W. Brown, G.C. Lesueur, and I.S. Russell Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women British Journal of Cancer 51 2 1985 271 278 (Pubitemid 15165083)
6. K.K. Khurana, A. Loosmann, P.J. Numann, and S.A. Khan Prophylactic mastectomy: pathologic findings in high-risk patients Archives of Pathology & Laboratory Medicine 124 3 2000 378 381 (Pubitemid 30152138)
7. S.R. Wellings, H.M. Jensen, and R.G. Marcum An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions Journal of the National Cancer Institute 55 2 1975 231 273
8. C.E. Alpers, and S.R. Wellings The prevalence of carcinoma in situ in normal and cancer-associated breasts Human Pathology 16 8 1985 796 807 (Pubitemid 15040815)
9. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study Journal of the National Cancer Institute 97 22 2005 1652 1662 (Pubitemid 41672231)
10. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Journal of the National Cancer Institute 90 18 1998 1371 1388 (Pubitemid 28439961)
11. R.T. Chlebowski, G.L. Anderson, and M. Gass Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women JAMA 304 15 2010 1684 1692
12. R.T. Chlebowski, S.L. Hendrix, and R.D. Langer Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial JAMA 289 24 2003 3243 3253 (Pubitemid 37430077)
13. R.T. Chlebowski, L.H. Kuller, and R.L. Prentice Breast cancer after use of estrogen plus progestin in postmenopausal women New England Journal of Medicine 360 6 2009 573 587
14. A.Z. LaCroix, R.T. Chlebowski, and J.E. Manson Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial JAMA 305 13 2011 1305 1314
15. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 3 2002 321 333 (Pubitemid 34761611)
16. M.L. Stefanick, G.L. Anderson, and K.L. Margolis Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy JAMA 295 14 2006 1647 1657
17. M.H. Gail, and P.L. Mai Comparing breast cancer risk assessment models Journal of the National Cancer Institute 102 10 2010 665 668
18. H.G. Welch, and W.C. Black Overdiagnosis in cancer [Review] [43 refs] Journal of the National Cancer Institute 102 9 2010 605 613
19. P.H. Zahl, J. Maehlen, and H.G. Welch The natural history of invasive breast cancers detected by screening mammography Archives of Internal Medicine 168 21 2008 2311 2316
20. K.J. Jorgensen, and P.C. Gotzsche Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends [Review] [34 refs] BMJ 339 2009 b2587
21. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer Cancer Prevention Research 3 6 2010 696 706
22. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial [Erratum appears in JAMA. 2007 September 5;298(9):973], [Erratum appears in JAMA. 2006 December 27;296(24):2926] JAMA 295 23 2006 2727 2741
23. P.E. Goss, J.N. Ingle, and J.E. es-Martinez Exemestane for breast-cancer prevention in postmenopausal women New England Journal of Medicine 364 25 2011 2381 2391
24. R.J. Santen, W. Yue, and D.F. Heitjan Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy Cancer Epidemiology, Biomarkers & Prevention 21 7 2012 1038 1048
25. J.S. Spratt, J.S. Meyer, and J.A. Spratt Rates of growth of human neoplasms: Part II [Review] [68 refs] Journal of Surgical Oncology 61 1 1996 68 83 (Pubitemid 26025133)
26. S.Y. Tan, G.J. van Oortmarssen, H.J. de Koning, R. Boer, and J.D. Habbema The MISCAN-Fadia continuous tumor growth model for breast cancer Journal of the National Cancer Institute 36 2006 56 65 (monographs)
27. D.B. Kopans, E. Rafferty, and D. Georgian-Smith A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena Cancer 97 12 2003 2951 2959 (Pubitemid 36676248)
28. R.J. Santen, W. Yue, and D.F. Heitjan Occult breast tumor reservoir: biologic properties and clinical significance Hormones and Cancer 2013 (in press)
29. B. Majed, A. Dozol, L. Ribassin-Majed, K. Senouci, and B. Asselain Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association Breast Cancer Research & Treatment 126 3 2011 729 738
30. R.X. Song, and R.J. Santen Apoptotic action of estrogen [Review] [63 refs] Apoptosis 8 1 2003 55 60 (Pubitemid 36133138)
31. J.H. Pickar, I.T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertility & Sterility 92 3 2009 1018 1024
32. D.F. Archer Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms [Review] [110 refs] Drugs & Aging 27 7 2010 533 544
33. J.A. Harvey, M.K. Holm, R. Ranganath, P.A. Guse, E.A. Trott, and E. Helzner The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis Menopause 16 6 2009 1193 1196
34. R.A. Lobo, J.V. Pinkerton, and M.L. Gass Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertility & Sterility 92 3 2009 1025 1038
35. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 2 2010 281 289
36. R. Lindsay Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE) [Review] Osteoporosis International 22 2 2011 447 451
37. G. Bachmann, J. Bobula, and S. Mirkin Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy Climacteric 13 2 2010 132 140
38. J.V. Pinkerton, and D.W. Stovall Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women [Review] Expert Opinion on Investigational Drugs 19 12 2010 1613 1621
39. J.V. Pinkerton, W.H. Utian, G.D. Constantine, S. Olivier, and J.H. Pickar Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 6 2009 1116 1124
40. J. Cuzick, T. Powles, and U. Veronesi Overview of the main outcomes in breast-cancer prevention trials [Review] [9 refs] Lancet 361 9354 2003 296 300 (Pubitemid 36126189)
41. S. Yan, R.J. Santen, W. Ji-ping, and Y. Wei Effects of the CE/BZA tisue selective estrogen complex on breast cancer in nude mice Endorinology 154 2013 651 665 (submitted 2012)
42. S. Yan, R.J. Santen, W. Ji-ping, and Y. Wei Inhibitory effects of a bazedoxifene/conjugated effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice Endocrinology 153 2012 5706 5715
43. T. Kim, H. Park, and W. Yue Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland Breast Cancer Research & Treatment 126 3 2011 779 789
44. W.S. Shim, M. Conaway, and S. Masamura Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo Endocrinology 141 1 2000 396 405 (Pubitemid 32260382)
45. Y. Song, R.J. Santen, J.P. Wang, and W. Yue Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice Endocrinology 153 12 2012 5706 5715
46. C.E. Wood, T.B. Clarkson, and H. Chen Comparative effects of oral conjugated equine estrogens and micronized 17beta-estradiol on breast proliferation: a retrospective analysis Menopause 15 5 2008 890 898
47. B. Fisher, S. Land, E. Mamounas, J. Dignam, E.R. Fisher, and N. Wolmark Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience Seminars in Oncology 28 4 2001 400 418 (Pubitemid 32762083)
48. S.K. Plevritis A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening Mathematical Biosciences 171 2 2001 155 178 (Pubitemid 32565744)
49. S.L. Bailey, B.M. Sigal, and S.K. Plevritis A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years Journal of the National Cancer Institute 102 16 2010 1263 1271
50. G.F. Robbins, and J.W. Berg Bilateral primary breast cancer; a prospective clinicopathological study Cancer 17 1964 1501 1527
51. P.P. Rosen, S. Groshen, D.W. Kinne, and S. Hellman Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up Surgery 106 5 1989 904 910 (Pubitemid 19283388)
52. G.L. Anderson, R.T. Chlebowski, and A.K. Aragaki Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial Lancet Oncology 13 5 2012 476 486
53. P. Fan, W. Yue, and J.P. Wang Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models Endocrinology 150 5 2009 2036 2045